Ou Yamaguchi

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 13

Top Topics

Interstitial Lung Disease

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Thoracic cancer

Cancer medicine

Cancer research

European journal of nuclear medicine and molecular imaging

This page only lists publications with an associated author ORCID identifier.

Publications

Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Kunihiko Kobayashi, Tomonori Kawasaki, Masanori Yasuda, Hiroshi Kagamu
Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib. Thoracic cancer (2023)
Ou Yamaguchi, Keita Mori, Saori Takata, Kazuhiko Shibata, Kenichi Chikamori, Nozomu Kimura, Yoshiaki Nagai, Taku Nakagawa, Satoshi Igawa, Taishi Harada, Hiroshige Yoshioka, Hisashi Tanaka, Hitomi Nogawa, Toshihiro Shiozawa, Toshihiro Shiozawa, Kosuke Tsuji, Kunihiko Kobayashi, Kyoichi Kaira
Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study). Thoracic cancer (2023)
Hisao Imai, Erika Naito, Ou Yamaguchi, Kosuke Hashimoto, Hidetoshi Iemura, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer. Thoracic cancer 13 (10) (2022)
Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano, Ou Yamaguchi, Atsuto Mouri, Ayako Shiono, Fuyumi Nishihara, Yu Miura, Kosuke Hashimoto, Hisao Imai, Kyoichi Kaira, Kunihiko Kobayashi, Yae Kanai, Tatsuhiro Shibata, Katsuhisa Horimoto
Single-cell analysis reveals a CD4+ T cell cluster that correlates with PD-1 blockade efficacy. Cancer research (2022)
Kyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, Ou Yamaguchi, Kosuke Hashimoto, Atsuto Mouri, Shun Shinomiya, Yu Miura, Hisao Imai, Hiroshi Kagamu
Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failure. Thoracic cancer 12 (6) (2021)
Hisao Imai, Ou Yamaguchi, Keita Mori, Kosuke Hashimoto, Tomoe Akagami, Shun Shinomiya, Yu Miura, Ayako Shiono, Atsuto Mouri, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. Thoracic cancer 12 (8) (2021)
Hisao Imai, Kyoichi Kaira, Kosuke Hashimoto, Hiroyuki Nitanda, Ryo Taguchi, Akitoshi Yanagihara, Tetsuya Umesaki, Ou Yamaguchi, Atsuto Mouri, Tomonori Kawasaki, Masanori Yasuda, Kunihiko Kobayashi, Hirozo Sakaguchi, Ichiei Kuji, Hiroshi Kagamu
Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor. Cancer medicine 10 (18) (2021)
Hisao Imai, Takayuki Kishikawa, Hiroyuki Minemura, Yutaka Yamada, Tatsuya Ibe, Ou Yamaguchi, Atsuto Mouri, Yoichiro Hamamoto, Kenya Kanazawa, Takashi Kasai, Kyoichi Kaira, Takayuki Kaburagi, Koichi Minato, Kunihiko Kobayashi, Hiroshi Kagamu
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. Cancer medicine 10 (20) (2021)
Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, Hiroshi Kagamu
Detection of pseudoprogression with [18F]-FDG-PET in a patient with pulmonary large cell neuroendocrine carcinoma who received anti-PD-1 treatment. European journal of nuclear medicine and molecular imaging 48 (4) (2020)
Ou Yamaguchi, Kyoichi Kaira, Shun Shinomiya, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Yu Miura, Tomoe Akagami, Hisao Imai, Kunihiko Kobayashi, Hiroshi Kagamu
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab. Thoracic cancer 12 (3) (2020)
Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin-Ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events. Thoracic cancer 11 (5) (2020)
Hisao Imai, Hiroyuki Minemura, Takayuki Kishikawa, Yutaka Yamada, Kensuke Suzuki, Yukihiro Umeda, Satoshi Wasamoto, Norimitsu Kasahara, Shinichi Ishihara, Ou Yamaguchi, Ichiro Naruse, Junji Uchino, Keita Mori, Kenya Kanazawa, Yoko Shibata, Takashi Kasai, Takayuki Kaburagi, Kyoichi Kaira, Koichi Minato
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis. Thoracic cancer 11 (10) (2020)
Ou Yamaguchi, Kyoichi Kaira, Tomonori Kawasaki, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Shun Shinomiya, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Satoshi Mochida, Hiroshi Kagamu
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation. Thoracic cancer 11 (4) (2020)